Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/jspui/handle/10553/167141
DC FieldValueLanguage
dc.contributor.authorUter, Wolfgangen_US
dc.contributor.authorWilkinson, S. Marken_US
dc.contributor.authorBauer, Andreaen_US
dc.contributor.authorBorrego Hernando, Leopoldoen_US
dc.contributor.authorBrans, Richarden_US
dc.contributor.authorBuhl, Timoen_US
dc.contributor.authorDickel, Heinrichen_US
dc.contributor.authorGallo, Rosellaen_US
dc.contributor.authorArnau, Ana Gimenezen_US
dc.contributor.authorGoncalo, Margaridaen_US
dc.contributor.authorKoumaki, Dimitraen_US
dc.contributor.authorNavarini, Alexander A.en_US
dc.contributor.authorPatruno, Cataldoen_US
dc.contributor.authorPonyai, Gyorgyien_US
dc.contributor.authorRustemeyer, Thomasen_US
dc.contributor.authorSpiewak, Radoslawen_US
dc.contributor.authorStingeni, Lucaen_US
dc.contributor.authorValiukeviciene, Skaidraen_US
dc.contributor.authorSchuttelaar, Marie-L. A.en_US
dc.contributor.authorAerts, Olivieren_US
dc.date.accessioned2026-05-25T13:57:06Z-
dc.date.available2026-05-25T13:57:06Z-
dc.date.issued2026en_US
dc.identifier.issn0105-1873en_US
dc.identifier.otherWoS-
dc.identifier.urihttps://accedacris.ulpgc.es/jspui/handle/10553/167141-
dc.description.abstractBackground: Allergens are periodically added to the European Baseline Series (EBS) to audit their value in consecutive patch testing. Objectives: To present results of audit allergens tested in consecutive patients in 54 departments in 13 European countries during 2021 and 2022. Methods: Anonymized or pseudonymized individual data, and partly aggregated data on patch test rest results and their clinical relevance were prospectively collected and centrally pooled and analyzed. Results: In 2021 and 2022, 18 832 patients were patch tested with the EBS, and 2860 with the TRUE Test baseline series (supplemented with some missing EBS allergens). Of these patients, 17 359 were additionally tested with one or more of the 19 audit allergen preparations examined. Apart from the terpene hydroperoxides (OOH) which yielded the highest numbers of positive patch test reactions (linalool-OOH 1% pet.: 7.65 (7.09%-8.23%) [95% CI] and limonene-OOH 0.3% pet. 6.78 (6.26%-7.32%)), positive reactions were most often seen to benzisothiazolinone (3.71 (3.3%-4.15%)), sodium metabisulfite (3.49 (3.14%-3.88%)), Evernia furfuracea (tree moss, 1.79 (1.4%-2.26%)), and decyl and lauryl glucoside, at 1.49 (1.25%-1.76%) and 1.26 (1.05%-1.51%), respectively. The other allergens yielded around 1% or fewer positive patch test reactions. Clinical relevance varied, with Evernia furfuracea, 2-bromo-2-nitropropane-1,3-diol and terpene hydroperoxides considered relevant in more than 2/3 cases, while for other frequent sensitizers benzisothiazolinone and sodium metabisulfite, relevance could be confirmed in half of the cases or less often. Conclusions: The current results, along with other published data, will serve to inform decisions concerning possible revision of the EBS, considering frequency of positive reactions, their clinical relevance and the overall reaction profile of each of the allergens.en_US
dc.languageengen_US
dc.relation.ispartofContact Dermatitisen_US
dc.sourceContact Dermatitis[ISSN 0105-1873], (Mayo 2026)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320106 Dermatologíaen_US
dc.subject.otherBaseline Seriesen_US
dc.subject.otherClinical Epidemiologyen_US
dc.subject.otherContact Allergyen_US
dc.subject.otherPatch Testingen_US
dc.subject.otherRrid:Scr_001905en_US
dc.subject.otherSurveillanceen_US
dc.titlePatch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCA<SUP>A</SUP> and the EBS<SUP>B</SUP> Working Groups of the ESCD, and the GEIDAC©en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/cod.70183en_US
dc.identifier.isi001766856000001-
dc.identifier.eissn1600-0536-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.description.numberofpages10en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Uter, W-
dc.contributor.wosstandardWOS:Wilkinson, SM-
dc.contributor.wosstandardWOS:Bauer, A-
dc.contributor.wosstandardWOS:Borrego, L-
dc.contributor.wosstandardWOS:Brans, R-
dc.contributor.wosstandardWOS:Buhl, T-
dc.contributor.wosstandardWOS:Dickel, H-
dc.contributor.wosstandardWOS:Gallo, R-
dc.contributor.wosstandardWOS:Arnau, AG-
dc.contributor.wosstandardWOS:Gonçalo, M-
dc.contributor.wosstandardWOS:Koumaki, D-
dc.contributor.wosstandardWOS:Navarini, AA-
dc.contributor.wosstandardWOS:Patruno, C-
dc.contributor.wosstandardWOS:Pónyai, G-
dc.contributor.wosstandardWOS:Rustemeyer, T-
dc.contributor.wosstandardWOS:Spiewak, R-
dc.contributor.wosstandardWOS:Stingeni, L-
dc.contributor.wosstandardWOS:Valiukeviciene, S-
dc.contributor.wosstandardWOS:Schuttelaar, MA-
dc.contributor.wosstandardWOS:Aerts, O-
dc.date.coverdateMayo 2026en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-0199-2756-
crisitem.author.fullNameBorrego Hernando, Leopoldo-
Appears in Collections:Artículos
Adobe PDF (396,18 kB)
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.